Homeβ€ΊSearchβ€ΊTranslational Breast Cancer Research

Translational Breast Cancer Research

AME Publishing Company Β· Hong Kong Β· Est. 2020

ISSN2218-6778eISSN2218-6778
SJR Q1βœ“ WOS ESCIβœ“ Scopus / SJR
90
/ 100
High Trust
PubScope credibility score from verifiable indexing & ethics signals
Score Breakdown
β—† Scopus Q178
βœ“ Corroboration (2 more)+12
Total90
Third-party records Β· how this is calculated Β· Report an error β†’
⚑ Speed vs Prestige
How does this journal balance review speed with impact level?
Publication speed: not measurable
publisher doesn’t disclose per-article submission dates β€” we never estimate
Q1
SJR Rank
Top 25% in field
Impact Factor & Quartile Β· Web of Science (JCR)

βœ“ Indexed in the Web of Science Core Collection (ESCI) β€” Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page β†—

The Impact Factor & JCR quartile are licensed by Clarivate β€” we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q1 Β· Scopus CiteScore 1.4. Source: Clarivate Journal Citation Reports.

SJR Scorei
0.891
H-Indexi
13
CiteScorei
1.4
SNIPi
0.166
Total Worksi
231
Total Citationsi
934
2yr Mean Citednessi
3.42
Open Impact Factor alternative

Aims & Scope

Translational Breast Cancer Research (TBCR) is an open access journal that publishes original research, reviews, commentaries, and expert consensus articles on all aspects of breast cancer, with a focus on translational research. The journal aims to bridge the gap between basic science and clinical practice, promoting the rapid translation of laboratory discoveries into clinical applications. TBCR covers a wide range of topics including breast cancer biology, diagnosis, treatment, prevention, and survivorship. The journal is committed to publishing high-quality, impactful research that advances the understanding and management of breast cancer.

General Information

Country / RegionHong Kong
Primary LanguageEnglish
1st Year Published2020
Annual Volume~ 35 articles / year
StatusActive (last: 2026)
Total Publications231
Publisher OrgAME Publishing Company
Region🌍 Global South
Visit Journal Website

Submission Info

Peer Reviewsingle-blind
Review Timeβ€”
Acceptance Rateβ€”
OA Licenseβ€”
OA Rateβ€”

Ethics & Quality

COPE Memberβœ— No
OASPA Memberβœ— No
Not on Predatory Listsβœ“ Yes
πŸ“¦ Long-term Preservation
PubMed Central (PMC)

Think.Check.Submit Compliance

8/12 Β· 67%
βœ…
Do you know the journal / publisher?
AME Publishing Company
βœ…
Does the journal have a website?
βœ“ Linked
βœ…
Is the ISSN verified?
2218-6778 / 2218-6778
βœ…
Indexed in a trusted database?
WoS, Scopus, PubMed
βœ…
Peer review process documented?
single-blind
❌
Follows ethical publishing standards (COPE)?
N/A
❌
APC fees clearly disclosed?
N/A
βœ…
Not on predatory/blacklists?
βœ“ Clean
βœ…
Long-term digital preservation?
PubMed Central (PMC)
❌
Plagiarism detection in place?
N/A
❌
Listed in DOAJ (verified OA)?
N/A
βœ…
Primary language documented?
English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published
Citations received
31
214
2020
39
99
2021
37
191
2022
29
169
2023
38
285
2024
39
90
2025
41
1
2026

Source: OpenAlex Β· Each year’s green bar = citations earned by that year’s papers, counted to date β€” so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category β€” its quartile can differ by discipline.

SurgeryQ1
OncologyQ2

Subject Classification

Web of Science Categories

Oncology

Scopus Categories

SurgeryOncology

Research Topics (OpenAlex)

Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Lesions and CarcinomasCancer Immunotherapy and BiomarkersCancer-related Molecular PathwaysMonoclonal and Polyclonal Antibodies ResearchCancer Cells and MetastasisBRCA gene mutations in cancer

Frequently asked questions about Translational Breast Cancer Research

Is Translational Breast Cancer Research a predatory journal?

PubScope has no integrity flags on record for Translational Breast Cancer Research: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Its PubScope Trust Score is 90/100. Indexing is a transparency signal, not a guarantee β€” always confirm fit and policies before submitting.

What is the impact factor of Translational Breast Cancer Research?

Translational Breast Cancer Research is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal β€” including Arts & Humanities and Emerging Sources titles β€” receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. As an open alternative, its Scopus CiteScore is 1.4.

Is Translational Breast Cancer Research indexed in Scopus and Web of Science?

Translational Breast Cancer Research is indexed in Web of Science, Scopus.

What is the aims and scope of Translational Breast Cancer Research?

Translational Breast Cancer Research (TBCR) is an open access journal that publishes original research, reviews, commentaries, and expert consensus articles on all aspects of breast cancer, with a focus on translational research. The journal aims to bridge the gap between basic science and clinical practice, promoting the rapid translation of laboratory discoveries into clinical applications. TBCR covers a wide range of topics including breast cancer biology, diagnosis, treatment, prevention, and survivorship. The journal is committed to publishing high-quality, impactful research that advance

Compare This JournalFind Similar← Back to Search
Understand these signals
How to tell if a journal is predatoryWhat Q1–Q4 quartiles meanWeb of Science vs Scopus vs DOAJWhat is an APC?

Data updated: 2026-05-22 Β· Sources: SJR, DOAJ, OpenAlex, WoS, Crossref